Research

Mixed

Combination therapies (e.g., Phentermine/Topiramate, Naltrexone/Bupropion) offer superior weight loss compared to monotherapy by targeting multiple pathways (appetite suppression and calorie absorption/reward), but carry higher risks of adverse effects and require strict monitoring.

Combination drugs like Phentermine/Topiramate can achieve nearly 11% weight loss, significantly better than placebo. They work by suppressing appetite and altering brain signaling. However, they have more side effects (dry mouth, taste disturbance, insomnia) and require careful monitoring for cognitive and cardiovascular effects. They are reserved for patients who need more than single-agent therapy.

GoodSupportsHIGH confidence
The EQUIP study... mean annual weight loss for individuals given the combination therapy was 10.9% (1.6% in the placebo group)... The bupropion/naltrexone combination... weight loss in subjects given the 32/360 mg combination therapy was 6.1%, 6.4%, and 9.3%... (1.3%, 1.2%, and 5.1% on placebo, respectively).
Pelin TİRYAKİOĞLU et al. · DAHUDER Medical Journal · 2023

Why this rating

Based on multiple large clinical trials (EQUIP, CONQUER, COR series).

Source

Current pharmacological approaches in obesity treatment

Pelin TİRYAKİOĞLU et al. · DAHUDER Medical Journal · 2023

DOI 10.56016/dahudermj.1271677

narrative_reviewCited 2×
Read the paper
DOI resolved against Crossref · corpus check 2026-06-10

This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →